Small molecule · developed by Sunshine Lake Pharma Co.
HEC585 is an oral once-daily tablet that is being studied in progressive fibrosing interstitial lung disease and idiopathic pulmonary fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07082842 | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) | Recruiting | SBFM |
| NCT05139719 | Phase 2 | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive… | Recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary Fibrosis (IPF)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →